A phase II study of carboplatin and paclitacel with meloxicam

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 72-76

  Suzuki, Ryujiro ^a   Yamamoto, Masashi ^b   Saka, Hideo ^b   Taniguchi, Hiroyuki ^b   Shindoh, Joe ^b   Tanikawa, Yoshimasa ^b   Nomura, Fumio ^b   Gonda, Hideo ^a   Imaizumi, Kazuyoshi ^b   Hasegawa, Yoshinori ^b   Shimokata, Kaoru ^b  

^a TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^b Central Japan Lung Study Group   (Japan)

Author keywords

Carboplatin; Meloxicam; Non small cell lung cancer; Paclitaxel; Selective cyclooxygenase 2 inhibitor; Weekly administration

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; MELOXICAM; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; SEX RATIO; SMALL INTESTINE PERFORATION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; THIAZINES; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 57649097578     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.04.002     Document Type: Article

References (35)

1. Rapp E., Pater J.L., Willan A., Cormier Y., Murray N., Evans W.K., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 6 (1988) 633-641
2. Wakelee H.A., Bernardo P., Johnson D.H., and Schiller J.H. Changes in the natural history of non-small cell lung cancer (NSCLC)-comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 106 (2006) 2208-2217
3. Bunn Jr. P.A., and Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4 (1998) 1087-1100
4. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 19 (2001) 3210-3218
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
6. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23 (2005) 5883-5891
7. Hosomi Y., Yokose T., Hirose Y., Nakajima R., Nagai K., Nishiwaki Y., et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30 (2000) 73-81
8. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn Jr. P.A., Chou T.C., et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59 (1999) 6178-6184
9. Hida T., Kozaki K., Ito H., Miyaishi O., Tatematsu Y., Suzuki T., et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 8 (2002) 2443-2447
10. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
11. Sawaoka H., Tsuji S., Tsujii M., Gunawan E.S., Sasaki Y., Kawano S., et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79 (1999) 1469-1477
12. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., and DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer. Cancer Res 58 (1998) 362-366
13. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
14. Irie T., Tsujii M., Tsuji S., Yoshio T., Ishii S., Shinzaki S., et al. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int J Cancer 121 (2007) 878-883
15. Altorki N.K., Port J.L., Zhang F., Golijanin D., Thaler H.T., Duffield-Lillico A.J., et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 11 (2005) 4191-4197
16. Hirabayashi M., Okuda M., Endoh K., Teramachi M., Yamaguchi K., Moriyama M., et al. Dose finding study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer. Jpn J Lung Cancer 41 (2001) 767-772
17. Takahashi T., Ueda S., Ebisawa M., Asai G., and Yamamoto N. Cyclooxygenase-2 (COX-2) inhibition with meloxicam in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22 (2004) 686S
18. Belani C.P., Barstis J., Perry M.C., La Rocca R.V., Nattam S.R., Rinaldi D., et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21 (2003) 2933-2939
19. Socinski M.A., Ivanova A., Bakri K., Wall J., Baggstrom M.Q., Hensing T.A., et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 17 (2006) 104-109
20. Nakadate M., Yamazaki K., Konishi J., Kinoshita I., Sukoh N., Harada M., et al. Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Anticancer Res 26 (2006) 3767-3772
21. Pujol J.L., Milleron B., Molinier O., Quoix E., Depierre A., Breton J.L., et al. Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. J Thorac Oncol 1 (2006) 328-334
22. Schuette W., Blankenburg T., Guschall W., Dittrich I., Schroeder M., Schweisfurth H., et al. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer 7 (2006) 338-343
23. Inoue A., Usui K., Ishimoto O., Matsubara N., Tanaka M., Kanbe M., et al. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 52 (2006) 83-87
24. Brown J.R., and DuBois R.N. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10 (2004) 4266s-4269s
25. Hida T. Overexpression of COX-2 and a potential clinical application of its inhibitors in lung cancer. Nippon Rinsho 62 (2000) 1357-1362
26. Altorki N.K., Keresztes R.S., Port J.L., Libby D.M., Korst R.J., Flieder D.B., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 14 (2003) 2645-2650
27. Lilenbaum R., Socinski M.A., Altorki N.K., Hart L.L., Keresztes R.S., Hariharan S., et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 24 (2006) 4825-4832
28. Gridelli C., Gallo C., Ceribelli A., Gebbia V., Gamucci T., Ciardiello F., et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8 (2007) 500-512
29. Arellano F.M. The withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 14 (2005) 213-217
30. Syriatowicz J.-P., Hu D., Walker J.S., and Tracey D.J. Hyperalgea due to nerve injury: role of prostaglandins. Neuroscience 94 (1999) 587-594
31. Levesque L.E., Brophy J.M., and Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142 (2005) 481-489
32. Garcia Rodriguez L.A., Varas-Lorenzo C., Maguire A., and Gonzalez-Perez A. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109 (2004) 3000-3006
33. Sun S.X., Lee K.Y., Bertram C.T., and Goldstein J.L. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 23 (2007) 1859-1866
34. Solomon D.H., Schneeweiss S., Glynn R.J., Kiyota Y., Levin R., Mogun H., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109 (2004) 2068-2073
35. Edelman M.J., Watson D.M., Wang X., Kratzke R.A., Mauer A.M., Green M.R., et al. Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203. J Clin Oncol 24 (2006) 370S